InterMune joins M&A fray

Share this article:

InterMune appears to be the latest M&A target. Bloomberg reports that drugmakers including GlaxoSmithKline, Actelion, Sanofi and Roche are rumored to be among a host of companies making a pitch to buy the business and own the company's experimental drug for idiopathic pulmonary fibrosis (IPF). William Blair analyst Katherine Xu tells Bloomberg that the company's experimental treatment looks to be better than Boehringer Ingelheim's experimental IPF therapy, echoing an opinion Jefferies analyst Eun Yang voiced in May.

JMP Securities analyst Liisa Bayko tells Bloomberg that a natural match would be a company with a foothold in the respiratory field.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters